Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

11/13/24 8:46:59 AM ET

$VANI

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $VANI alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get started Learn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds: Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters: Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk: Multitask with confidence and let Quantsinow read breaking news out loud.

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts: Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications: Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks: Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts: Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get started Learn more

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

Live feeds
Audio squawk
Compact mode in feeds
Email alerts
App push alerts
Unlimited insights reads
Unlimited subscriptions
Advanced filters in live feeds
Support
No ads
AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time

5 million+

Real-time news alerts sent out to Quantisnow users

700,000+

Latency of news delivery pipelines to users via mobile app, webhooks, and email

<100ms

Get the next $VANI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VANI

Date	Price Target	Rating	Analyst

More analyst ratings

$VANI
Press Releases

Fastest customizable press release news feed in the world

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into the second quarter of 2026, supporting further development of NPM-139 and NPM-115 programs in chronic weight management ALAMEDA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"),
3/31/25 7:30:00 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a p
3/27/25 7:32:56 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing smooth and steady delivery of GLP-1 therapy ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company de
3/26/25 7:30:00 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$VANI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4/4/25 8:21:50 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4/1/25 7:00:49 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
3/3/25 7:23:04 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$VANI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4/4/25 8:21:50 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4/1/25 7:00:49 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
3/3/25 7:23:04 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$VANI
SEC Filings

SEC Form 10-K filed by Vivani Medical Inc.
10-K - Vivani Medical, Inc. (0001266806) (Filer)
3/31/25 8:45:49 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
3/31/25 8:40:17 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
3/27/25 9:11:14 AM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$VANI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
5/1/23 8:42:07 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
SEC Form SC 13D filed by Vivani Medical Inc.
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)
4/25/23 5:28:48 PM ET
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)

Weekly insight reads limit reached.

Meet Quantisnow

Invest smarter

Save time

Get alerted immediately

Elevate your trading.Start using Quantisnow today.

Simple no-tricks pricing

Quantisnow Plus

What's included

Chat with this insight

Recent Analyst Ratings for $VANI

$VANI Press Releases

Fastest customizable press release news feed in the world

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vivani Medical Announces $8.25M Private Placement Equity Financing

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

$VANI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)

$VANI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)

Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)

$VANI SEC Filings

SEC Form 10-K filed by Vivani Medical Inc.

Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

$VANI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

SEC Form SC 13D filed by Vivani Medical Inc.

Elevate your trading.
Start using Quantisnow today.

Recent Analyst Ratings for
$VANI

$VANI
Press Releases

$VANI
Insider Purchases

$VANI
Insider Trading

$VANI
SEC Filings

$VANI
Large Ownership Changes